Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)

Abstract:
Bexion Pharmaceuticals announced today that it has been awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI).

Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)

Covington, KY | Posted on October 11th, 2010

The grant entitled "SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme" was awarded September 28, 2010 and covers a two year period. This announcement from NCI follows their September 20, 2010 announcement selecting Bexion for a notable research collaboration with NCI's Nanotechnology Characterization Laboratory (NCL), part of a major program, the Alliance for Nanotechnology in Cancer, to advance the medical applications of nanotechnology.

Bexion's proprietary technology is based on Saposin C- dioleoylphosphatidylserine (dubbed "SapC-DOPS") and is a first-in-class nanovesicle therapeutic for the treatment of glioblastomas (GBM), pancreatic cancers, and other solid tumors. These nanovesicles have preferential affinity for phosphatidylserine-enriched membrane patches which appear to be common in many types of tumor cells and tumor neovasculature. Bexion's initial studies of SapC-DOPS nanovesicles have shown that
they induce apoptosis in cancer cell lines and also demonstrated in vivo efficacy in multiple tumor models.

The intent of this Phase II SBIR grant is to identify and select optimized SapC-DOPS formulations and treatment methods for glioblastoma multiforme, suitable for advancing Bexion's drug toward planned human testing. Upon the completion of these studies, Bexion expects to have compelling evidence to progress into clinical development.

"This Phase II award will expedite our goal to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment," stated Dr. Ray Takigiku, Bexion's co-founder and CEO. "Of the 12,000 patients expected to be diagnosed with GBM this year, most will succumb within the first year. Clearly, there is an urgent demand for an efficacious anti-glioma drug."

This SBIR Phase II award is the fourth grant won by Bexion from the NCI. Past awards include Phase I grants for treating Metastatic Prostate, Pancreatic and Glioblastoma Multiforme.

####

About Bexion Pharma
Bexion Pharmaceuticals is focused on the development and commercialization of innovative cures for cancer. Initial products are based on a proprietary platform technology licensed from Cincinnati Children’s Hospital Medical Center. The technology has demonstrated potential for development as therapeutics, diagnostic and surgical imaging reagents, and as carriers for other pharmaceutical agents, such as oligonucleotides. For more information, visit www.bexionpharma.com.

For more information, please click here

Contacts:
Margaret van Gilse
VP, Business Development
Bexion Pharmaceuticals, LLC
632 Russell Street
Covington, KY 41011
Phone: (513) 833-7065

Copyright © Bexion Pharma

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Discovery of new Li ion conductor unlocks new direction for sustainable batteries: University of Liverpool researchers have discovered a new solid material that rapidly conducts lithium ions February 16th, 2024

$900,000 awarded to optimize graphene energy harvesting devices: The WoodNext Foundation's commitment to U of A physicist Paul Thibado will be used to develop sensor systems compatible with six different power sources January 12th, 2024

Catalytic combo converts CO2 to solid carbon nanofibers: Tandem electrocatalytic-thermocatalytic conversion could help offset emissions of potent greenhouse gas by locking carbon away in a useful material January 12th, 2024

'Sudden death' of quantum fluctuations defies current theories of superconductivity: Study challenges the conventional wisdom of superconducting quantum transitions January 12th, 2024

Nanobiotechnology

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project